Using bulk RNA sequencing and multicolor-immunohistochemistry, we demonstrated that IGFBP2 was significantly reduced in AEC2 cells from patients with COVID-ARDS, IPF alone, or IPF with a history of COVID-19 (IPF with COVID history) compared with healthy donor controls. Here, IGFBP2 is linked to COVID-19.